COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine)
Checked 2026-09-09
Consolidation after OEPA in intermediate- and advanced-stage childhood Hodgkin lymphoma; COPP (procarbazine in place of dacarbazine) is the older version
Also called COPDAC, COPP.
One cycle
every 28 days × 2-4 · about 8 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug) | 500 mg/m² | IV | D1, 8 | |
Vincristine Vinca alkaloid (microtubule inhibitor) | 1.5 mg/m² (maximum 2 mg) | IV | D1, 8 | |
Prednisone Glucocorticoid | 40 mg/m² once daily | Oral | D1-15 | |
Dacarbazine Alkylating agent (triazene) | 250 mg/m² | IV | D1-3 |
Cycles
2-4
28-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Notes
- Dacarbazine replaced procarbazine to avoid infertility in boys, with the same event-free survival.
- EuroNet-PHL-C2 tested intensified COPDAC-28 to reduce the need for radiotherapy.
Used in
Source
Mauz-Körholz (GPOH-HD-2002), JCO 2010: procarbazine-free OEPA-COPDAC in boys and OPPA-COPP in girls
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
ABVD
Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage
every 28 days × 2-6
BV-AVD
Stage III-IV classical Hodgkin lymphoma
every 28 days × 6
N-AVD (nivolumab + AVD)
Stage III-IV classical Hodgkin lymphoma, age 12 and above
every 28 days × 6
ICE
Relapsed or refractory aggressive lymphoma and Hodgkin lymphoma, salvage and stem cell mobilisation before autologous transplant (R-ICE when rituximab is added)
every 14 days × 2-3
Escalated BEACOPP
Advanced-stage classical Hodgkin lymphoma in fit patients under 60, PET-adapted to 4-6 cycles
every 21 days × 4-6
MOPP
Historical: the first curative combination chemotherapy for advanced Hodgkin lymphoma (1960s to 1980s), replaced by ABVD
every 28 days × 6
Stanford V
Historical 12-week regimen with consolidative radiotherapy for advanced Hodgkin lymphoma; not superior to ABVD in the US Intergroup E2496 trial
every 28 days × 3
ABVE-PC
Children and adolescents with intermediate- and high-risk Hodgkin lymphoma in Children's Oncology Group trials, response-adapted with or without radiotherapy
every 21 days × 4-5